“AstraZeneca unveiled successes in the treatment of lung cancer on Monday, with its leading drug slowing progression of the disease at an early stage.

Its best-selling Tagrisso drug showed a ‘statistically significant and highly clinically meaningful’ improvement in preventing the progression of a version of the most common form of the disease, the company said.”

From Financial Times.